New chemo drug gentler on fertility, tougher on cancer
In a pre-clinical study using mice, a new gentler chemotherapy drug in the form of nanoparticles packed with the chemotherapy drug, arsenic trioxide, has been designed by Northwestern Medicine scientists to be less toxic to a young woman’s fertility but extra tough on cancer. This is the first cancer drug tested while in development for its effect on fertility using a novel in vitro test. Northwestern is home to the Robert H. Lurie Comprehensive Cancer Center.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.